Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D3 Plus K2 for BPPV Recurrence
NCT07861464Phase 1Completed
- Sponsor
- University of Jordan
- Start
- Jan 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of menaquinone in benign paroxysmal positional vertigo (BPPV) (3 arms), sponsored by University of Jordan. Primary endpoint: Recurrence rate of BPPV at 12 months. Started Jan 2025; status: completed.
02
Drugs
menaquinone
03
Conditions
benign paroxysmal positional vertigo (BPPV)
Beyond the preview
Go deeper on NCT07861464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07861464.